lurasidone

Lurasidone is a second-generation (atypical) antipsychotic drug primarily indicated for the treatment of schizophrenia and depressive episodes associated with bipolar I disorder. It acts mainly as an antagonist at dopamine D2, serotonin 5-HT2A, and 5-HT7 receptors, with additional activity as a partial agonist at 5-HT1A receptors and antagonist at adrenergic α2C receptors. Lurasidone was developed by Sumitomo Dainippon Pharma (formerly Dainippon Sumitomo Pharma) and first approved by the US FDA in 2010 for schizophrenia, later expanding to include bipolar depression. The drug is administered orally and is known for its relatively favorable metabolic side effect profile compared to other atypical antipsychotics[1][2][4][6].

Brand names

Latuda

Other names

鲁拉西酮